Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...

Myocarditis III: Medical Management

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Myasthenia Gravis: Overview and Treatment

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Upadacitinib for recalcitrant extraintestinal Crohn disease.

JAAD case reports·2026

Same author

Characterizing superficial epidermolytic ichthyosis in a patient with KRT2 mutation responsive to ustekinumab.

JAAD case reports·2026

Same author

Generalized bullous fixed drug eruption related to intravenous contrast.

Dermatology online journal·2025

Same author

Evolution of Subacute Cutaneous Lupus Erythematosus.

JAMA dermatology·2025

Same author

Lupus miliaris disseminatus faciei: A unique presentation with extrafacial involvement.

Dermatology online journal·2025

Same author

Erythromelalgia and the Association With Paraproteinemias: A Retrospective Case Series.

International journal of dermatology·2025

Search research articles

Related Experiment Video

Updated: Jul 3, 2026

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy

Published on: October 31, 2025

Immunomodulatory treatment for dermatomyositis.

Jeffrey P Callen¹

¹Division of Dermatology, University of Louisville, 310 East Broadway, Louisville, KY 40202, USA. jefca@aol.com

Current Allergy and Asthma Reports

|July 9, 2008

Summary

Dermatomyositis and polymyositis, types of idiopathic inflammatory myopathies, have differing muscle disease causes but similar treatments. Corticosteroids are initial therapy, often combined with corticosteroid-sparing agents for long-term management.

Related Experiment Videos

Last Updated: Jul 3, 2026

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy

Published on: October 31, 2025

Area of Science:

Rheumatology
Immunology
Dermatology

Background:

Dermatomyositis and polymyositis are idiopathic inflammatory myopathies.
Recent findings suggest distinct muscle disease pathogenesis for each.
Current therapies for muscle disease are similar, while skin treatment varies slightly.

Purpose of the Study:

To define dermatomyositis and its systemic manifestations.
To update the selection and evaluation of immunomodulatory, corticosteroid-sparing agents.
To discuss current therapeutic approaches for idiopathic inflammatory myopathies.

Main Methods:

Review of current literature on dermatomyositis and polymyositis.
Analysis of therapeutic strategies, including corticosteroids and corticosteroid-sparing agents.
Discussion of disease management and patient outcomes.

Main Results:

Corticosteroids are the primary treatment, often requiring high doses for skin manifestations.
Corticosteroid-sparing agents are frequently added early to mitigate side effects and improve management.
Some patients experience disease remission, while others require ongoing maintenance therapy.

Conclusions:

Effective management of dermatomyositis and polymyositis involves a combination of therapies.
Selection of appropriate immunomodulatory agents is crucial for long-term disease control.
Further research into distinct pathogenetic mechanisms may lead to more targeted therapies.